 |
|
|
| |
Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable?
|
| |
| |
Reported by Jules Levin
AASLD 2017 Wash DC October 20-24
Download the PDF here
Johannes Vermehren1, Julia Dietz1, Simone Susser1, Eckart Schott2, Jörn M. Schattenberg3, Eugen Zizer4, Julian Schulze zur Wiesch5, Christoph Antoni6, Perdita Wietzke-Braun7, Claus Niederau8, Stefan Mauss9, Jurgen K. Rockstroh10, Beat Mullhaupt11, Rudolf E. Stauber12, Stefan Zeuzem1, Christoph Sarrazin1,13; 1Medizinische Klinik 1,
Universitatsklinikum Frankfurt, Frankfurt am Main, Germany; 2Charité Universitatsmedizin Berlin, Berlin, Germany; 3Universitatsklinikum Mainz, Mainz, Germany; 4Universitatsklinikum Ulm, Ulm, Germany; 5Universitatsklinikum Eppendorf, Hamburg, Germany; 6Universitatsklinikum Mannheim, Mannheim, Germany; 7Universitatsklinikum Schleswig-Holstein, Kiel, Germany; 8Katholisches Klinikum Oberhausen, Oberhausen, Germany; 9Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 10Universitatsklinikum Bonn, Bonn, Germany; 11Universitatsspital Zurich, Zurich, Switzerland; 12Medizinische Universitat Graz, Graz, Austria; 13St Josefs Hospital, Wiesbaden, Germany
AASLD: Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and Clinical Isolates From Direct-Acting Antiviral-Experienced and -Naïve Patients - (10/26/17)
AASLD: SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study - (10/23/17)
|
| |
|
|
|
|
|
